{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:31:46Z","timestamp":1786422706315,"version":"build-2736575974"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cca.2026.121132","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:20:08Z","timestamp":1780417208000},"page":"121132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia"],"prefix":"10.1016","volume":"591","author":[{"given":"Riya","family":"Thapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj Kumar","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif Ahmad","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omji","family":"Porwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Tahir","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Narain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangita","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivkanya","family":"Fuloria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121132_bb0005","first-page":"41","article-title":"Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification, Cancer","volume":"13","author":"Kansal","year":"2016","journal-title":"Biol. Med."},{"key":"10.1016\/j.cca.2026.121132_bb0010","first-page":"39","article-title":"Novel therapeutic options in acute myeloid leukemia","volume":"6","author":"Medinger","year":"2016","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.cca.2026.121132_bb0015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121132_bb0020","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121132_bb0025","doi-asserted-by":"crossref","unstructured":"M. Jongen-Lavrencic, T. Grob, D. Hanekamp, F.G. Kavelaars, A. al Hinai, A. Zeilemaker, et al., Molecular minimal residual disease in acute myeloid leukemia, N. Engl. J. Med. 378 (2018) 1189\u20131199.","DOI":"10.1056\/NEJMoa1716863"},{"key":"10.1016\/j.cca.2026.121132_bb0030","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood.V98.6.1752","article-title":"The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy","volume":"98","author":"Kottaridis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0035","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies","volume":"11","author":"Yokota","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0045","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0050","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0055","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121132_bb0060","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1182\/blood-2007-08-109090","article-title":"The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia","volume":"111","author":"Gale","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S1525-1578(10)60458-8","article-title":"Detection of FLT3 internal tandem duplication and D835 mutations by a multiplex polymerase chain reaction and capillary electrophoresis assay","volume":"5","author":"Murphy","year":"2003","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121132_bb0070","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41379-019-0359-9","article-title":"Hybridization capture-based next-generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia","volume":"33","author":"He","year":"2020","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cca.2026.121132_bb0075","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood.V85.7.1762.bloodjournal8571762","article-title":"The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors","volume":"85","author":"Hirayama","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0080","first-page":"588","article-title":"Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells","volume":"10","author":"Drexler","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0085","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.leu.2400921","article-title":"FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates","volume":"12","author":"Lavagna-S\u00e9venier","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0090","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0095","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2007-05-091215","article-title":"Prognostic relevance of FLT3-TKD mutations in AML: the combination matters","volume":"111","author":"Bacher","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2004-07-2942","article-title":"AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations","volume":"106","author":"Choudhary","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0105","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/sj.onc.1205332","article-title":"Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain","volume":"21","author":"Kiyoi","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cca.2026.121132_bb0110","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0115","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1182\/blood-2014-05-578070","article-title":"Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation","volume":"124","author":"Schlenk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0120","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/cancers15041312","article-title":"Clinical implications of the FLT3-ITD allelic ratio in acute myeloid leukemia in the context of an allogeneic stem cell transplantation","volume":"15","author":"Jentzsch","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121132_bb0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","article-title":"Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results","volume":"36","author":"R\u00fccker","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0130","article-title":"The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia","volume":"13","author":"Sakaguchi","year":"2020","journal-title":"Leuk. Res. Rep."},{"key":"10.1016\/j.cca.2026.121132_bb0135","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3390\/genes16060684","article-title":"A modified FLT3 PCR assay using a TapeStation readout","volume":"16","author":"Blake","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.cca.2026.121132_bb0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pathol.2022.07.004","article-title":"Clinically relevant variation in FLT3-ITD quantitation as a result of PCR cycle number and ITD insertion size","volume":"55","author":"Tiong","year":"2023","journal-title":"Pathology"},{"key":"10.1016\/j.cca.2026.121132_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13000-022-01202-x","article-title":"A comparative study of next-generation sequencing and fragment analysis for the detection and allelic ratio determination of FLT3 internal tandem duplication","volume":"17","author":"Kim","year":"2022","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.cca.2026.121132_bb0150","article-title":"The analytical performance and inter-laboratory standardization of next-generation sequencing panels for genetic risk stratification in acute myeloid leukemia","volume":"18","author":"Alqurain","year":"2026","journal-title":"Cureus"},{"key":"10.1016\/j.cca.2026.121132_bb0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jmoldx.2012.08.001","article-title":"Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data","volume":"15","author":"Spencer","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121132_bb0160","article-title":"FLT3-TKD measurable residual disease detection using droplet digital PCR and clinical applications in acute myeloid leukemia","volume":"25","author":"Li","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121132_bb0165","doi-asserted-by":"crossref","first-page":"7662","DOI":"10.1021\/acs.analchem.4c04750","article-title":"Ultrasensitive detection of FLT3-ITD mutations via primer competition enhanced mutant accumulation","volume":"97","author":"Dai","year":"2025","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2026.121132_bb0170","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.61","article-title":"Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.cca.2026.121132_bb0175","doi-asserted-by":"crossref","first-page":"31284","DOI":"10.18632\/oncotarget.5161","article-title":"Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients","volume":"6","author":"Zuffa","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2026.121132_bb0180","doi-asserted-by":"crossref","first-page":"30128","DOI":"10.18632\/oncotarget.25729","article-title":"Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia","volume":"9","author":"Schranz","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cca.2026.121132_bb0185","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.jmoldx.2021.07.012","article-title":"Accurate detection and quantification of FLT3 internal tandem duplications in clinical hybrid capture next-generation sequencing data","volume":"23","author":"Tung","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121132_bb0190","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1038\/s41375-023-01884-2","article-title":"Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia","volume":"37","author":"Rausch","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0195","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1038\/s41598-024-57295-5","article-title":"Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia","volume":"14","author":"Song","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121132_bb0200","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2005-06-2248","article-title":"Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype","volume":"106","author":"Schnittger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0205","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2012-06-431122","article-title":"Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation","volume":"121","author":"Pratcorona","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0210","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0215","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2026.121132_bb0220","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2005-04-1746","article-title":"Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia","volume":"106","author":"Gale","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0225","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1182\/blood.2019003339","article-title":"Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis","volume":"135","author":"Bezerra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0230","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13045-014-0074-4","article-title":"Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations","volume":"7","author":"Loghavi","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0235","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1002\/cncr.34495","article-title":"Molecular profiling of patients with cytogenetically normal acute myeloid leukemia and hyperleukocytosis","volume":"128","author":"Pastore","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.cca.2026.121132_bb0240","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1182\/bloodadvances.2023010173","article-title":"Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting","volume":"7","author":"Attardi","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.121132_bb0245","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2005-08-3453","article-title":"Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia","volume":"107","author":"Stirewalt","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0250","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.bbmt.2015.10.023","article-title":"Allogeneic stem cell transplantation improves survival in patients with acute myeloid leukemia characterized by a high allelic ratio of mutant FLT3-ITD","volume":"22","author":"Ho","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.cca.2026.121132_bb0255","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0260","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1600-0609.2004.00225.x","article-title":"Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients","volume":"72","author":"Andersson","year":"2004","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.cca.2026.121132_bb0265","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood-2006-03-009233","article-title":"Clinical implications of FLT3 mutations in pediatric AML","volume":"108","author":"Meshinchi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0270","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/bloodadvances.2017009019","article-title":"Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.121132_bb0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood.2018883140","article-title":"NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia","volume":"134","author":"Rudorf","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0280","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1182\/bloodadvances.2020002904","article-title":"Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial","volume":"4","author":"Voso","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.121132_bb0285","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.2018.191809","article-title":"Impact of FLT3-ITD length on prognosis of acute myeloid leukemia","volume":"104","author":"Liu","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.cca.2026.121132_bb0290","doi-asserted-by":"crossref","first-page":"20745","DOI":"10.1038\/s41598-021-00050-x","article-title":"Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens","volume":"11","author":"Casta\u00f1o-Bonilla","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121132_bb0295","doi-asserted-by":"crossref","first-page":"456.e1","DOI":"10.1016\/j.jtct.2023.03.033","article-title":"FLT3-ITD allelic ratio and NPM1 mutation do not impact outcomes in acute myeloid leukemia patients with FLT3-ITD after allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Zhou","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.cca.2026.121132_bb0300","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41375-022-01650-w","article-title":"Genomic landscape of patients with FLT3-mutated acute myeloid leukemia treated within the CALGB 10603\/RATIFY trial","volume":"36","author":"Jahn","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0305","doi-asserted-by":"crossref","first-page":"23565","DOI":"10.1038\/s41598-021-03010-7","article-title":"FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML","volume":"11","author":"Kivioja","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cca.2026.121132_bb0310","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0315","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121132_bb0320","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood-2024-201058","article-title":"10-year follow-up of CALGB 10603\/RATIFY: midostaurin versus placebo plus intensive chemotherapy in newly diagnosed FLT3-mutant acute myeloid leukemia patients aged 18\u201360 years","volume":"144","author":"Stone","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0325","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cca.2026.121132_bb0330","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0335","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2026.121132_bb0340","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0345","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.cca.2026.121132_bb0350","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0355","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1182\/blood-2025-767","article-title":"Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed\/refractory acute myeloid leukemia: results from a randomized, placebo-controlled, double-blind trial","volume":"146","author":"Cluzeau","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0360","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2009-03-209999","article-title":"Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome","volume":"114","author":"Kayser","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0365","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.3390\/cancers14174315","article-title":"Overcoming resistance: FLT3 inhibitors past, present, future and the challenge of cure","volume":"14","author":"Capelli","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121132_bb0370","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.121132_bb0375","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ajh.70053","article-title":"Cytomolecular mechanisms of relapse and post-relapse outcomes after frontline FLT3 inhibitor-based therapy in FLT3-mutated AML","volume":"100","author":"Arora","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2026.121132_bb0380","doi-asserted-by":"crossref","first-page":"63","DOI":"10.36922\/EJMO025150101","article-title":"Dynamics of FLT3 mutations in acute myeloid leukemia: a systematic review and meta-analysis of shifts between diagnosis and relapsed\/refractory disease","volume":"9","author":"Teixeira","year":"2025","journal-title":"Eurasian J. Med. Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0385","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000545384","article-title":"STREAMLINE: retrospective cohort study of FMS-like tyrosine kinase 3-mutated acute myeloid leukemia","volume":"149","author":"Zeidan","year":"2026","journal-title":"Acta Haematol."},{"key":"10.1016\/j.cca.2026.121132_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14145110","article-title":"Real-world outcomes in FLT3-ITD-mutated acute myeloid leukemia","volume":"14","author":"Vecchio","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2026.121132_bb0395","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14218\/JCTP.2025.00008","article-title":"Molecular testing of FLT3 mutations in hematolymphoid malignancies in the era of next-generation sequencing","volume":"5","author":"Koga","year":"2025","journal-title":"J. Clin. Transl. Pathol."},{"key":"10.1016\/j.cca.2026.121132_bb0400","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/cells14191526","article-title":"Counter-therapeutic strategies for resistance of FLT3 inhibitors in acute myeloid leukemia","volume":"14","author":"Song","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.cca.2026.121132_bb0405","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2002-02-0420","article-title":"Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia","volume":"100","author":"Kottaridis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0410","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1182\/blood-2002-01-0195","article-title":"Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0415","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/sj.leu.2404246","article-title":"Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples","volume":"20","author":"Cloos","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2026.121132_bb0420","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/modpathol.2012.88","article-title":"Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients","volume":"25","author":"Warren","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cca.2026.121132_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100534","article-title":"Clonal dynamics and relapse risk revealed by high-sensitivity FLT3-internal tandem duplication detection in acute myeloid leukemia","volume":"37","author":"Oduro","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.cca.2026.121132_bb0430","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00277-020-04026-1","article-title":"Pre-transplant FLT3\/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation","volume":"99","author":"Helbig","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cca.2026.121132_bb0435","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0440","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.cca.2026.121132_bb0445","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.cca.2026.121132_bb0450","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41409-024-02444-7","article-title":"Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Hegde","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.cca.2026.121132_bb0455","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jmoldx.2018.09.009","article-title":"Clinical utility of a next-generation sequencing panel for acute myeloid leukemia diagnostics","volume":"21","author":"Alonso","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.cca.2026.121132_bb0460","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1182\/bloodadvances.2022009008","article-title":"Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions versus central laboratories","volume":"7","author":"Borate","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2026.121132_bb0465","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050854","article-title":"Conventional PCR versus next-generation sequencing for diagnosis of FLT3, IDH and NPM1 mutations in acute myeloid leukemia","volume":"17","author":"Boluda","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121132_bb0470","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OTT.S526628","article-title":"Multiclonal profiling of FLT3-ITD in AML using MinION sequencing","volume":"18","author":"Mart\u00ednez-Serra","year":"2025","journal-title":"Onco. Targets Ther."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126003141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T04:17:49Z","timestamp":1786421869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126003141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":94,"alternative-id":["S0009898126003141"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121132","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121132","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121132"}}